As shown in Figure 5A, SPARC plasma levels in ductal carcinoma (DC) and in bone metastasis (ME)-bearing patients doubled and tripled, respectively, compared to that of normal women (CTR). This evidence concerns the gene SPARC and breast ductal adenocarcinoma.